Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
about
Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parametersEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityThe role of regulatory T cells in cancer immunologyB cells inhibit the antitumor immunity against an established murine fibrosarcomaUnderstanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsDownregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12/IFNγ signaling.Murine lung cancer induces generalized T-cell exhaustion.TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomasPlasma membrane vesicles decorated with glycolipid-anchored antigens and adjuvants via protein transfer as an antigen delivery platform for inhibition of tumor growthDiffering patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.Programmed death-1 checkpoint blockade in acute myeloid leukemia.Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma.Cancer immunoprevention.PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival.Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models.Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.Autoimmunity as a double agent in tumor killing and cancer promotion.Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune PathwaysIs antigen specificity the key to efficient adoptive T-cell therapy?Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation.The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).Therapeutic cancer vaccines: a long and winding road to success.Immunoregulatory activity of adenosine and its role in human cancer progression.Induced regulatory T cells in inhibitory microenvironments created by cancer.Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV.Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck.Pharmacological Modulation of Proton Channel Hv1 in Cancer Therapy: Future Perspectives.Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice.Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.Prognostic value of peripheral and local forkhead box P3(+) regulatory T cells in patients with non-small-cell lung cancer.Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease.Adenoviral-transduced dendritic cells are susceptible to suppression by T regulatory cells and promote interleukin 17 production.Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity.Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
P2860
Q24615872-03EF78D2-A0FF-4529-886D-267CDAE48C60Q26796313-4BA73B35-5C93-4A59-BDFF-FFE72730AA52Q27006663-97158302-7180-4487-AEA1-C246D12DCD90Q33684762-1888BA37-E0C2-4A20-8911-CF1876B33A7FQ33698419-30F33F72-4D71-4AAB-A4E5-FD92C2027F79Q33839267-8BC45FFB-385D-40C1-8D76-46298DBD4418Q35562860-91CDB2BF-AAD2-4DE7-B443-EFA3CE3852EDQ35958114-2A44C64E-D0A5-4815-850E-6425A143F141Q36211422-689CA2FD-A796-4B2A-91B4-EDB26E4E7856Q36322686-AE3A2A26-7BF7-4BDC-9077-CF50E9E82536Q36443331-70FCC9AE-C3FA-47D3-9513-C24045314BDCQ36652124-D3907DF0-785F-4F1C-A6CF-43D2D0C9D141Q36670900-5BEC2CDF-49B1-46F8-ADEA-0DE881C8F450Q36723234-149982D4-5781-4FA7-9545-E83FF7C51D1FQ36897208-4868A9E4-3560-436B-A160-E6C6EC7402DFQ37126642-7550EC22-1411-4C95-9A3E-075A0B98E4F0Q37548776-DA1B5832-8825-4EA7-B91B-7BEE509081B1Q37642271-2EF75ABC-5646-44CD-8C04-8AB4F35D6191Q37690959-D9437C51-E07D-4D7B-8E3A-71980B8D2DADQ37861214-C7D15C4E-744E-4273-BC02-6F6DCCEA51EBQ37894107-9C144912-4E0E-416A-A9B9-03BD6A38EAD6Q37956691-ED05FDBF-D928-4A37-8FA7-CDEDAF8EFA9BQ38162261-3FF84B60-4B5D-4C9D-89DC-017F95D40663Q38215678-5433D661-7C46-4B43-8E1E-B1FD59BDB0CDQ38220701-4A0DFE1E-6049-41C0-8644-0D65583C615CQ38266807-99FC4823-D2A0-4C69-B2B9-1D3944A325D5Q38800033-7F97CB88-EE08-4832-A202-311BE1B19D36Q38853680-3E607BB5-A898-4BFC-ADB7-CCB86903FBD7Q39472057-19AFB192-A685-4DCD-800B-866D9C46334AQ41623726-78034D91-0CA1-4BF7-A8F9-F6E040222CC9Q42743141-264A413E-58F4-498F-B3A6-136B7BADC55BQ43075747-50496F6D-49B2-4A52-B496-B1A2F16651BDQ44626008-8B7BA2DF-D094-4731-9E4D-0C828AEE8222Q50020665-EE83E2A9-DBBB-4A7D-9EBB-BAA47E8F03DAQ50484749-90C6F9DC-6B72-4AF5-8830-ED6C38EE0131Q56523838-11ACE55C-0E4F-4D87-98A3-B20287C7F50C
P2860
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
@ast
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
@en
type
label
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
@ast
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
@en
prefLabel
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
@ast
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
@en
P2860
P1476
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
@en
P2093
Theresa L Whiteside
P2860
P304
P356
10.1517/14712598.2010.482207
P407
P577
2010-07-01T00:00:00Z